Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387150 | 0.94 | CYP19A1 (0.47) | PNMTDRD2DRD3CYP19A1MCHR1 | |
| SCHEMBL3101907 | 0.87 | PNMT (0.49) | PNMTDRD2DRD3CYP19A1MCHR1 | |
| SCHEMBL3101900 | 0.87 | PNMT (0.49) | PNMTDRD2DRD3CYP19A1MCHR1 | |
| SCHEMBL11211912 | 0.76 | DRD2 (0.46) | PNMTDRD2DRD3CYP19A1MCHR1 | |
| SCHEMBL25554143 | 0.76 | CYP19A1 (0.42) | DRD2DRD3CYP19A1MCHR1 | |
| SCHEMBL9752117 | 0.76 | DRD2 (0.57) | PNMTDRD2DRD3KDM1A | |
| SCHEMBL6971110 | 0.73 | DRD2 (0.46) | PNMTDRD2DRD3KDM1A | |
| SCHEMBL11210812 | 0.73 | CYP3A4 (0.51) | PNMTDRD2DRD3CYP19A1MCHR1 | |
| SCHEMBL6570371 | 0.72 | CYP19A1 (0.54) | CYP19A1 | |
| SCHEMBL15701675 | 0.72 | CYP19A1 (0.54) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | PNMT 1090/4885DRD2 3279/4885DRD3 3268/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | PNMT 1090/4885DRD2 3279/4885DRD3 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.